- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07471139
SWITCH : Apixaban contre vitamine K dans HM3
L'essai SWITCH : Une étude randomisée contrôlée comparant l'apixaban aux antagonistes de la vitamine K chez les patients porteurs d'un dispositif d'assistance ventriculaire gauche HeartMate 3
This study is being done to learn the safety and efficacy of a new anticoagulant therapy with apixaban as compared to warfarin to prevent thrombotic events while protecting from bleeding complications in patients with advanced heart failure who are chronically supported by a HeartMate 3 Left Ventricular Assist Device for 3 months.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Heart failure is a global epidemic, and Left Ventricular Assist Devices (LVADs) - particularly the HeartMate 3 (HM3) - are increasingly used due to their survival benefit over medical therapy. Despite advances, hemocompatibility-related adverse events (HRAEs) like thrombosis and bleeding remain significant causes of morbidity and mortality.
Direct Oral Anticoagulants (DOACs) have shown superiority over warfarin in heart failure patients, with lower rates of embolic and intracranial bleeding. Reduced-dose DOACs also appear to reduce major bleeding without increasing thrombotic risk. However, data on their use in LVAD patients is limited, consisting mainly of case reports, small series, retrospective analyses, and a few small randomized clinical trials.
Some reports suggest apixaban may reduce bleeding in high-risk LVAD patients, though cases of pump thrombosis and stroke have occurred. Early studies comparing DOACs to warfarin in patients with HeartMate II (HMII), HeartWare™ HVAD™ System, and The Abbott HeartMate 3 (HM3) show no significant differences in outcomes, with a trend toward less bleeding with apixaban. Two small randomized clinical trials in HM3 patients (The DOAC LVAD Study and The DOT-HM3 Study) found similar results.
This prospective, randomized, controlled, non-inferiority trial will evaluate the safety and efficacy of apixaban versus vitamin K antagonists in HM3 patients more than 3 months post-implant.
Type d'étude
Inscription (Estimé)
Phase
- Phase 3
Contacts et emplacements
Coordonnées de l'étude
- Nom: Ilan Richter, MD
- Numéro de téléphone: 3322098345
- E-mail: ir2498@cumc.columbia.edu
Lieux d'étude
-
-
New York
-
New York, New York, États-Unis, 10032
- Recrutement
- Columbia University Irving Medical Center
-
Contact:
- Ilan Richter, MD
- Numéro de téléphone: 212-305-7600
- E-mail: ir2498@cumc.columbia.edu
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Participants will have HeartMate3 LVAD implanted > 3 months before enrollment
- ≥ 18 years old
- Treated with WARFARIN SODIUM
- Participant must provide written informed consent prior to any clinical investigation related procedure
- In female participants of childbearing capability, not currently pregnant and on appropriate contraception
Exclusion Criteria:
- Participation in any other clinical investigation(s) involving a Mechanical Circulatory Support (MCS) device, or interventional investigation(s) likely to confound study results or affect study outcome
- Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results
- Known allergy to Apixaban
- Bridge to transplant
- Severe renal dysfunction Estimated Glomerular Filtration Rate (eGFR) <20
- History of major bleeding event with subsequent reduction of INR goal to < 1.8
- Apixaban dose reduction criteria (Age ≥80 years, weight ≤60 kg, creatinine ≥1.5 mg/dL)
- Aortic root thrombus
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: Warfarin
Participants will take warfarin, dose titrated for an INR >= 1.8 |
Warfarin dose titrated for an International Normalized Ratio (INR) >= 1.8
Autres noms:
|
|
Expérimental: Apixaban
Participants wil take apixaban 5 mg bid |
Apixaban 5 mg bid (twice a day)
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Survival free of major hemocompatibility related adverse event
Délai: 12 months
|
Major Hemocompatibility Related Adverse Event: Stroke, Pump Thrombosis, major non surgical Bleeding (moderate or severe), Arterial Peripheral Thromboembolism. Rates will be compared between study groups. |
12 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Non-surgical Major Hemorrhagic Events
Délai: 12 months
|
Rates will be compared between study groups. |
12 months
|
|
Non-surgical Major Thrombotic Events
Délai: 12 months
|
Rates will be compared between study groups. |
12 months
|
|
Survival
Délai: 12 months
|
Rates will be compared between study groups. |
12 months
|
|
Stroke Rates
Délai: 12 months
|
Rates will be compared between study groups. |
12 months
|
|
Pump Thrombosis Rates
Délai: 12 months
|
Rates will be compared between study groups. |
12 months
|
|
Bleeding Rates
Délai: 12 months
|
Rates will be compared between study groups. |
12 months
|
|
Rates of listing for Heart Transplant
Délai: 12 months
|
Rates will be compared between study groups. |
12 months
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Niveaux d'apixaban chez les patients présentant un événement indésirable
Délai: 12 mois
|
12 mois
|
|
|
Patient functional status
Délai: 12 months
|
Association between anticoagulant regimen and New York Heart Association (NYHA) Functional Classification (FC) will be compared between groups. Scores range I through IV, with higher scores indicating worse outcome. |
12 months
|
|
Patient QOL
Délai: 12 months
|
Kansas City Cardiomyopathy Questionnaire (KCCQ) 12 scores will be compared between groups. Scores range 1-100, with higher scores indicating better health status. |
12 months
|
|
LVAD device speed
Délai: 12 months
|
LVAD speed (mean, SD) of LVAD will be compared between study groups. Speed ranges 4500-6000 RPM. |
12 months
|
|
LVAD device flow
Délai: 12 months
|
LVAD flow (mean, SD) of LVAD will be compared between study groups. Flow ranges 3-6 L/min. |
12 months
|
|
LVAD device pulsatility index
Délai: 12 months
|
LVAD pulsatility index (PI) will be compared between study groups. PI ranges 1-4 (no units). |
12 months
|
|
LVAD device power
Délai: 12 months
|
LVAD power (mean, SD) will be compared between study groups. Power ranges 3-7 W. |
12 months
|
|
Right atrial pressure
Délai: 12 months
|
Right atrial (RA) pressure (mean, SD) will be compared between study groups. RA ranges 0-20 mmHg. |
12 months
|
|
Right ventricular systolic pressure
Délai: 12 months
|
Right ventricular (RV) systolic pressure (mean, SD) will be compared between study groups. RV systolic pressure ranges 0-100 mmHg. |
12 months
|
|
Right ventricular diastolic pressure
Délai: 12 months
|
Right ventricular (RV) diastolic pressure (mean, SD) will be compared between study groups. RV diastolic pressure ranges 0-50 mmHg. |
12 months
|
|
Pulmonary artery systolic pressure
Délai: 12 months
|
Pulmonary artery (PA) systolic pressure (mean, SD) will be compared between study groups. PA systolic pressure ranges 0-100 mmHg. |
12 months
|
|
Pulmonary artery diastolic pressure
Délai: 12 months
|
Pulmonary artery (PA) diastolic pressure (mean, SD) will be compared between study groups. PA diastolic pressure ranges 0-50 mmHg. |
12 months
|
|
Pulmonary artery mean pressure
Délai: 12 months
|
Pulmonary artery (PA) mean pressure (mean, SD) will be compared between study groups. PA mean pressure ranges 0-50 mmHg. |
12 months
|
|
Pulmonary capillary wedge pressure
Délai: 12 months
|
Pulmonary capillary wedge pressure (PCWP, mean, SD) will be compared between study groups. PCWP ranges 0-50 mmHg. |
12 months
|
|
Cardiac output
Délai: 12 months
|
Cardiac output (CO, mean, SD) will be compared between study groups. CO ranges 3-10 L/min. |
12 months
|
|
Invasive hemodynamics
Délai: 12 months
|
Cardiac index (CI, mean, SD) will be compared between study groups. CI ranges 2.5-4 L/min/m^2. |
12 months
|
|
Drive line infection rates
Délai: 12 months
|
Rate of drive line infections will be compared between study groups. |
12 months
|
|
VAD coordinator time
Délai: 12 months
|
Means will be compared between study groups. |
12 months
|
|
Laboratory monitoring
Délai: 12 months
|
A quantitative comparison of performed laboratory tests to monitor anticoagulation between groups (counts) |
12 months
|
|
Days hospitalized
Délai: 12 months
|
Means will be compared between study groups. |
12 months
|
|
Caregiver burden
Délai: 12 months
|
Self assessed caregiver burden will be collected using the validated The Oberst Caregiving Burden Scale (OCBS), and compared between study groups. Scores range 15-75, with higher scores indicating higher levels of caregiving burden (more time spent or greater difficulty). |
12 months
|
|
Time in therapeutic range in the warfarin sodium group
Délai: 12 months
|
Means, as well as rates above 70%, will be compared between study groups. |
12 months
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Nir Uriel, MD, New York Presbyterian / Columbia University Medical Center
Publications et liens utiles
Publications générales
- Netuka I, Tucanova Z, Ivak P, Gregor S, Kolesar DM, Marek T, Melenovsky V, Binova J, Dorazilova Z, Hegarova M, Podolec M, Riha H, Connors JM, Mehra MR. A Prospective Randomized Trial of Direct Oral Anticoagulant Therapy With a Fully Magnetically Levitated LVAD: The DOT-HM3 Study. Circulation. 2024 Aug 6;150(6):509-511. doi: 10.1161/CIRCULATIONAHA.124.069726. Epub 2024 Apr 9. No abstract available.
- Shah P, Looby M, Dimond M, Bagchi P, Shah B, Isseh I, Rollins AT, Abdul-Aziz AA, Kennedy J, Tang DG, Klein KM, Casselman S, Vermeulen C, Sheaffer W, Snipes M, Sinha SS, O'Connor CM. Evaluation of the Hemocompatibility of the Direct Oral Anticoagulant Apixaban in Left Ventricular Assist Devices: The DOAC LVAD Study. JACC Heart Fail. 2024 Sep;12(9):1540-1549. doi: 10.1016/j.jchf.2024.04.013. Epub 2024 May 7.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Troubles cérébrovasculaires
- Maladies du cerveau
- Maladies du système nerveux central
- Maladies du système nerveux
- Maladies vasculaires
- Maladies cardiovasculaires
- Processus pathologiques
- Maladies cardiaques
- Embolie et thrombose
- Conditions pathologiques, signes et symptômes
- Accident vasculaire cérébral
- Insuffisance cardiaque
- Thrombose
- Hémorragie
- Composés hétérocycliques, 1 anneau
- Composés hétérocycliques
- Composés hétérocycliques, 2 anneaux
- Composés hétérocycliques, anneau fusionné
- Pyrans
- Coumarines
- Benzopyrans
- 4-hydroxycoumarines
- Warfarine
- apixaban
Autres numéros d'identification d'étude
- AAAV9532
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .